The role of proteasome inhibition in nonsmall cell lung cancer Article

Santos, ES, Escobar, M, Velez, M et al. (2011). The role of proteasome inhibition in nonsmall cell lung cancer . 2011 10.1155/2011/806506

cited authors

  • Santos, ES; Escobar, M; Velez, M; Belalcazar, A; Raez, LE



  • Lung cancer therapy with current available chemotherapeutic agents is mainly palliative. For these and other reasons there is now a great interest to find targeted therapies that can be effective not only palliating lung cancer or decreasing treatment-related toxicity, but also giving hope to cure these patients. It is already well known that the ubiquitin-proteasome system like other cellular pathways is critical for the proliferation and survival of cancer cells; thus, proteosome inhibition has become a very attractive anticancer therapy. There are several phase I and phase II clinical trials now in non-small cell lung cancer and small cell lung cancer using this potential target. Most of the trials use bortezomib in combination with chemotherapeutic agents. This paper tends to make a state-of-the-art review based on the available literature regarding the use of bortezomib as a single agent or in combination with chemotherapy in patients with lung cancer. Copyright 2011 Mauricio Escobar et al.

publication date

  • June 24, 2011

Digital Object Identifier (DOI)


  • 2011